Adocia Sa · EURONEXT:ADOC
Adocia Sa — Investor Presentation (April 2024)
18 slides from Adocia Sa's investor presentation, April 2024
Slide 1: Innovative BioTherapies From Diabetes to Obesity
Innovative BioTherapies From Diabetes to Obesity Olivier Soula, Founder & CEO (ADOC)
Slide 2: Forward-looking statements
Forward-looking statements This corporate presentation (the “Presentation”) has been prepared by ADOCIA S.A. (the “Company” and, together with its subsidiary, the “Group”) and is provided for information purposes only. It is not for promotional use. References herein to the Presentation shall mean a
Slide 3: Adocia, 20 years dedicated to developing drugs for metabolic diseases
Adocia, 20 years dedicated to developing drugs for metabolic diseases 2005 2012 80 people Founded by the $135m from 25 patent IPO 35 partnerships families Soula family ADOC PhD/MD/PharmD Lyon, France - Focus: Developing innovative treatments in diabetes and obesity - Business model: Partnering produ
Slide 4: Focused on innovation, turned towards partnerships
Focused on innovation, turned towards partnerships Preclinic Phase 1 Phase 2 Phase 3 Status / Upcoming milestones Partner SHORT TERM OBESITY in EXCLUSIVITY AGREEMENT (10M€) CATALYSTS M1Pram T1 DIABETES PARTNERING DISCUSSIONS ONGOING AdoShell DIABETES Discussions with FIRST IN HUMAN PREPARATION Islet
Slide 5: M1Pram: Insulin & amylin analogs combination
M1Pram Insulin & amylin analogs combination Addressing the unmet need of obesity in insulin-dependent people 5 5
Slide 6: The revolution of satiety hormones
The revolution of satiety hormones GLP-1 AMYLIN Physiologically secreted by pancreatic β cells Weight loss, glycemic control, CV benefits Appetite, Food intake, delayed gastric emptying To stimulate β cells that secrete To replace missing amylin amylin Treatment of choice in people with β cells
Slide 7: M1Pram, a novel combination of insulin and amylin
To address the unmet need of insulin-dependent individuals with obesity, we have developed M1Pram, a novel combination of insulin and amylin Gold Standard Mealtime Insulin M1Pram = Insulin + Amylin ✓ Same number and time of injections ✓ Same glycemic control maintained ✓ Same risk of hypoglycemia ✓
Slide 8: M1Pram has demonstrated exceptional weight loss in obese T1D
M1Pram has demonstrated exceptional weight loss in obese T1D CT041 : Phase 2 study – M1Pram vs. lispro (Humalog®) - type 1 diabetes GLP-1s are not approved in T1D → Associated with risk of ketosis and hypo/hyperglycemia1 Insulin lispro (Humalog®) -0.57 kg (-0.74%), N=9 Closest population for compari
Slide 9: U.S. market estimates: potential first-line treatment for people with obesity under intensive insulin therapy
U.S. market estimates: potential first-line treatment for people with obesity under intensive insulin therapy Large & Growing Price Unmet Chronic & patient parity with Medical Vital GLP-1 Blockbuster reservoir Need treatment potential 2 million $12,000 (U.S.) /year (U.S.) No competitive product has
Slide 10: M1Pram development plan & key value inflexion points
M1Pram development plan & key value inflexion points Sanofi has acquired for €10m a time-limited exclusive right to negotiate a worldwide licensing transaction Ph. 2b results in T1D and Ph. 3 readiness Phase 2 Proof-of-Concept Next development steps Exceptional weight loss in T1D while - Clinical ba
Slide 11: AdoShell Islets
AdoShell® Islets Toward a cure for type 1 diabetes 11 11
Slide 12: AdoShell Islets: the promise of cell therapy without immunosuppression
AdoShell® Islets: the promise of cell therapy without immunosuppression Islet transplantation is approved and practiced in routine in many countries Application is limited due to AEs of immunosuppressants used to avoid rejection AdoShell Islets, an immunoprotective hydrogel encapsulating cells ✓ All
Slide 13: AdoShell: Biocompatible hydrogel scaffold for cell therapy
AdoShell®: Biocompatible hydrogel scaffold for cell therapy Biocompatible Immuno-isolation polymers Ab, T cells Large entities >10nm AdoShell® Islets + + Free diffusion Oxygen, Glucose, Insulin 132-day study in diabetic Insulin-secreting Small entities <5nm immunocompetent rats cells AdoShell Islets
Slide 14: AdoShell Islet development plan & key value inflection points
AdoShell® Islet development plan & key value inflection points Partnering IP generation Preclinical POC Adocia files a patent on a hydrogel scaffold with human islets for cell therapy in the treatment of T1D in diabetic mice 2021 2022 2023 2024 First-in-Human Efficacy evidence in animal Oral present
Slide 15: Financials & Conclusions
Financials & Conclusions 15 15
Slide 16: Key financials
Key financials Shareholder ownership March 22nd, 2024 • Cash position – as of March 22, 2024: €10.2m • Equity line: w. optional 1.7m shares with Vester Finance (extending Free float Soula Family & cash runway to Q3 2025) 69,0% Employees Pool 12,8% • Indebtedness: €5.6m (PGE debt maturing Aug. 2026)
Slide 17: 2024/2025: Major inflexion points potentially transforming value
2024/2025: Major inflexion points potentially transforming value 2024 2025 M1Pram 1 Major partnership Licensing transaction w. Sanofi Launch Ph. 2b in U.S. Ph. 2b Results (T1D patients w. obesity) AdoShell® Unique technology for cell 2 therapy Preclinical POC triggering a partnership Launch First In
Slide 18: Thank you for your interest
Thank you for your interest 115 avenue Lacassagne 69003 Lyon – FRANCE Ph.:+33 4 72 610 610 contactinvestisseurs@adocia.com (ADOC)